Abstract
Angiogenic biomarkers, including soluble fms-like tyrosine kinase 1 (sFlt1), are thought to be predictors of preeclampsia onset; however, improvement is needed before a widespread diagnostic test can be utilized. Here we describe the development and use of diagnostic monoclonal antibodies specific to the two main splice variants of sFlt1, sFlt1-1 and sFlt1-14. These antibodies were selected for their sensitivity and specificity to their respective sFlt1 isoform in a capture ELISA format. Data from this pilot study suggest that sFlt1-1 may be more predictive of preeclampsia than total sFlt1. It may be possible to improve current diagnostic platforms if more specific antibodies are utilized.
Keywords:
diagnostic; isoforms; monoclonal antibody (mAb); preeclampsia; soluble fms-like tyrosine kinase 1 (sFlt1); splice variants.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alternative Splicing / immunology
-
Amniotic Fluid / immunology
-
Amniotic Fluid / metabolism
-
Animals
-
Antibodies, Monoclonal / metabolism*
-
CHO Cells
-
Cricetulus
-
Female
-
Humans
-
Mice
-
Pilot Projects
-
Pre-Eclampsia / blood
-
Pre-Eclampsia / diagnosis*
-
Pre-Eclampsia / immunology
-
Pregnancy
-
Pregnancy Proteins / blood*
-
Pregnancy Proteins / genetics
-
Pregnancy Proteins / immunology
-
Protein Isoforms / blood
-
Protein Isoforms / genetics
-
Protein Isoforms / immunology
-
Sensitivity and Specificity
-
Vascular Endothelial Growth Factor Receptor-1 / blood*
-
Vascular Endothelial Growth Factor Receptor-1 / genetics
-
Vascular Endothelial Growth Factor Receptor-1 / immunology*
Substances
-
Antibodies, Monoclonal
-
Pregnancy Proteins
-
Protein Isoforms
-
FLT1 protein, human
-
Vascular Endothelial Growth Factor Receptor-1